Volume | 1,244,136 |
|
|||||
News | (1) | ||||||
Day High | 4.7999 | Low High |
|||||
Day Low | 4.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Jaguar Health Inc | JAGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.76 | 4.02 | 4.7999 | 4.03 | 4.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,076 | 1,244,136 | $ 4.26 | $ 5,295,611 | - | 0.0512 - 7.68 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:06:23 | 20 | $ 4.07 | USD |
Jaguar Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
204.55M | 50.76M | - | 9.76M | -41.3M | -0.81 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jaguar Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JAGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1601 | 7.68 | 0.1219 | 0.3105793 | 16,996,626 | 3.92 | 2,448.41% |
1 Month | 0.2166 | 7.68 | 0.1219 | 0.2776598 | 53,136,870 | 3.86 | 1,783.66% |
3 Months | 0.1259 | 7.68 | 0.0645 | 0.168183 | 64,239,299 | 3.95 | 3,140.67% |
6 Months | 0.33 | 7.68 | 0.0512 | 0.1524118 | 42,268,438 | 3.75 | 1,136.36% |
1 Year | 0.6791 | 7.68 | 0.0512 | 0.1663447 | 22,393,000 | 3.40 | 500.80% |
3 Years | 126.00 | 228.00 | 0.0512 | 15.46 | 10,308,177 | -121.92 | -96.76% |
5 Years | 933.45 | 1,273.50 | 0.0512 | 60.16 | 10,517,144 | -929.37 | -99.56% |
Jaguar Health Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. |